Primary entity: Bremelanotide (PT-141)Also known as: VyleesiClass: FDA-approved melanocortin agonist peptideCluster: Melanocortin
PT-141 is the research/development code commonly used for bremelanotide, a melanocortin receptor agonist peptide. In the U.S. it is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women under labeled conditions. Gray-market “PT-141 research peptide” vials are not the same as the approved product — a major AI/forum conflation this page closes.
Approved-product decisions belong with a licensed clinician and the current FDA label. We do not publish DIY dosing charts, male “performance protocols,” or buy links. Disclaimer.
FDA-approved as Vyleesi (bremelanotide) for premenopausal women with acquired generalized HSDD (with labeled limitations — not for men, not for postmenopausal women, not as a performance enhancer). Compounded or RUO “PT-141” is not Vyleesi.
Key takeaways
- PT-141 = bremelanotide; approved U.S. brand Vyleesi for a specific HSDD indication.
- Label limits matter: not indicated for men or postmenopausal women; not a sexual-performance enhancer claim.
- Melanocortin agonist class — related folk adjacency to Melanotan peptides (different entities/risks).
- RUO “PT-141” ≠ approved autoinjector product.
- No DIY dosage chart on this site.
Questions this page answers
Next questions we answer on this page (curiosity / AI-gap map):
- What is PT-141?
- Also known as / Vyleesi
- Classification
- What it is NOT
- Mechanism
- Evidence ladder
- Approved / studied
- Safety literacy
- Regulatory status
- Why no dosages
- Related melanocortins
- Who for / not for
Who is this profile for — and who is it not for?
For: readers who need approved-vs-research literacy for bremelanotide / PT-141 and melanocortin class clarity.
Not for: anyone seeking DIY peptide protocols, off-label self-experiment charts, or medical advice.
What is PT-141?
Bremelanotide (PT-141) is a cyclic peptide melanocortin receptor agonist. The approved product Vyleesi is a subcutaneous autoinjector medicine used as needed under labeled conditions for eligible premenopausal women with HSDD. Mechanism of clinical benefit in HSDD is not fully established on-label; melanocortin receptor engagement (including MC4R-relevant CNS pathways in research framing) is the class literacy point.
Related: What are peptides?.
| INN / code | Bremelanotide · PT-141 |
|---|---|
| U.S. brand | Vyleesi |
| Class | Melanocortin receptor agonist peptide |
| Approved population (label) | Premenopausal women with acquired generalized HSDD — |
| RUO vials | Not interchangeable with Vyleesi |
Also known as
- Bremelanotide — nonproprietary name.
- Vyleesi — FDA-approved brand.
- PT-141 / PT141 — development/research code still dominant in forums.
- Related folk adjacency: Melanotan I/II — different melanocortin peptides with different risk stories.
Approved product identity, device, sterility, and labeling are not guaranteed for anonymous RUO vials. Treat them as a different regulatory object.
How is PT-141 / bremelanotide classified?
As Vyleesi, it is an FDA-approved peptide drug with prescribing information. As “PT-141” in research-chemical markets, it is often sold outside that pathway — classification literacy is the point of this profile’s split callouts.
What is PT-141 not?
| PT-141 / bremelanotide is not… | Why that matters |
|---|---|
| A male sexual-performance drug on-label | Label limitations — not indicated for men |
| Melanotan II | Related class family; different entity |
| Unrestricted libido peptide for anyone | Indication-specific approval |
| Something we DIY-dose | Refusal |
How is it thought to work?
Bremelanotide activates multiple melanocortin receptors (potency order discussed in labeling/research). MC4R-relevant central pathways are often cited in educational explainers for sexual-desire biology; the label states the precise mechanism for HSDD improvement is unknown. Pigmentation themes relate partly to MC1R biology — a labeled risk literacy topic (focal hyperpigmentation).
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Approved-label / Phase 3 | HSDD program supporting Vyleesi approval | Approved-label / Human |
| Other populations | Not established as labeled indications (e.g., men) | None on-label |
| Animal / discovery | Melanocortin sexual-behavior models (historical) | Animal |
| Forum RUO anecdotes | Not evidence | None |
What has it been approved / studied for?
Approved (U.S.): Vyleesi for premenopausal women with acquired generalized HSDD under labeled criteria and limitations. Not labeled as a general sexual-performance enhancer, and not indicated for men or postmenopausal women per standard label framing — .
What safety topics appear on labels?
Label-aware literacy themes include nausea, transient blood-pressure increase / heart-rate decrease, focal hyperpigmentation, injection-site reactions, and contraindications such as uncontrolled hypertension or known cardiovascular disease. This is literacy, not a substitute for reading the full PI with a clinician. Not medical advice.
What is its regulatory status?
- U.S.: FDA-approved as Vyleesi (bremelanotide) — .
- RUO “PT-141”: Not the approved product pathway.
- Sport: Check current WADA/GlobalDRO if relevant to melanocortin analogues — — separate from FDA approval.
Why doesn't this page include a dosage chart?
Labeled dosing exists for the approved product under clinician care. This educational page still refuses DIY charts and off-label self-experiment schedules for research vials. Patients: use official prescribing information.
Related lab literacy
Not applicable for approved autoinjector use beyond labeled Instructions for Use. RUO reconstitution how-tos are not a PT-141 protocol.
Related compounds and comparisons
- Melanotan-2 (MT-II) — related melanocortin-class research peptide with a different (unapproved) tanning folklore and risk profile than PT-141 / Vyleesi.
- Nootropics hierarchy — not a nootropic; linked only for taxonomy clarity if confused.
- What are peptides?.
Frequently asked questions
Is PT-141 the same as Vyleesi?
PT-141 is the code name for bremelanotide. Vyleesi is the FDA-approved brand. RUO vials labeled PT-141 are not automatically Vyleesi.
Is PT-141 FDA approved?
Bremelanotide is FDA-approved as Vyleesi for a specific HSDD indication in premenopausal women. That is not a blanket approval for all uses or populations.
Can men use PT-141 / Vyleesi?
Vyleesi is not indicated for men on the standard U.S. label framing. This page does not provide off-label protocols.
Is PT-141 a Melanotan?
No. It is a related melanocortin-class peptide with a different approved story than Melanotan products.
Why no dosage chart?
DIY/RUO protocol demand. Approved-product dosing is clinician-directed via the label — not a forum chart.
Vyleesi is a prescription medicine. Educational only. Disclaimer.
Sources
- Label U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection prescribing information. Label updated November 9, 2026 (setid f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf). Accessed November 10, 2026.
- Primary — human Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500. PMID: 31599840.
- Internal Peptide Tutorials. Melanotan-2; Disclaimers. Approved Vyleesi is not interchangeable with gray-market “PT-141” vials.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Nov 10, 2026 · Labels, trial citations, and WADA list wording checked Nov 10, 2026 · How we source & update
Educational disclaimer: Educational only. Bremelanotide (Vyleesi) is a prescription medicine. No DIY dosing or buy links. We don’t sell peptides. Read our full disclaimers.